|
Identifying and Treating the Methamphetamine Abuser
Methamphetamine may have overtaken heroin as the fourth most common drug-related reason for emergency department visits. The author reviews the startling statistics, describes the drug’s acute and long-term effects, and outlines the differential diagnosis and management of methamphetamine toxicity.
By Mark A. Graber, MD
|
Dr. Graber is professor of emergency medicine and family medicine at the University of Iowa Carver College of Medicine in Iowa City. He is also a member of the EMERGENCY MEDICINE editorial board. |
A 24-year-old man presents to the emergency department after being picked up by the police on a Saturday night. The patient was found standing outside his car on a city street, screaming and gesturing belligerently at the vehicle. He told the police that the car was filled with snakes that were coming out of the glove box and from under the seats.
In the emergency department, the patient is aggressive and uncooperative. The emergency physician notes increasing agitation, random muscle twitching, and shortness of breath. Rales and an S3 gallop are detected on the chest exam, suggesting the possible presence of congestive heart failure (CHF). His blood pressure is 230/140.
The physician needs to choose appropriate drugs for both sedation and control of the patient’s elevated blood pressure, which may have induced some degree of CHF.
She also realizes that there is a very good chance, given this patient’s history and the physical exam findings, that he is a methamphetamine user.
WIDELY ABUSED DRUG
Methamphetamine is a stimulant drug that is widely abused in the United States. It is estimated that 0.6% of the adult population in the United States (approximately 1.4 million people) abused methamphetamine in 2004, the most recent year for which data are available. Unlike many other drugs, methamphetamine use is especially common in rural areas: for example, 4.6% of 18- to 25-year-olds in Wyoming reported having used methamphetamine compared to just 0.3% in the state of New York. This is likely due to the availability of the ingredients needed to make methamphetamine in agricultural communities, such as anhydrous ammonia, which is used to add nitrogen to soil.
However, much of the methamphetamine used in the United States today is made by drug traffickers in Mexico, which has changed the distribution pattern. Disturbingly, urban centers are catching up with rural communities. In Newark, New Jersey, the number of methamphetamine-related emergency department visits increased by a startling 574% over a seven-year period; other urban areas have seen triple-digit increases. The Drug Abuse Warning Network (DAWN) (see Suggested Reading) estimates that methamphetamine was responsible for approximately 102,843 emergency department visits in 2004, making it the fifth most common drug-related reason for such visits after alcohol (461,809), cocaine (383,350), marijuana (215,665), and heroin (162,137). It is likely, according to the same DAWN report, that methamphetamine-related visits have now overtaken heroin.
Methamphetamine’s ability to increase sexual pleasure has also led to an epidemic of its use among homosexual men. An unfortunate consequence of this trend is a doubling of high-risk sexual behavior, leading to an increase in sexually transmitted diseases, including HIV/AIDS.
LONG HISTORY OF USE
Stimulants and amphetamine-like drugs have a long history of use. The medicinal use of ma huang (ephedrine) is reported in China over 5000 years ago. Leaves of the coca plant, from which cocaine is derived, have been chewed in Central and South America for at least 2000 years. Alexander the Great recommended the use of khat, a small shrub that contains an amphetamine-like stimulant, to one of his generals for depression. Khat continues to be used widely in East Africa and parts of the Middle East.
Amphetamines were first synthesized around 1887; methamphetamine itself was first synthesized in Japan in 1919. Modern interest in stimulants, however, did not begin until the 1920s, when ephedrine was used to treat asthma. Widespread use of stimulants ensued. During World War II, amphetamines were supplied to troops and workers on all sides to increase alertness and reduce fatigue. This resulted in an epidemic of amphetamine abuse, especially in Japan and Sweden.
Amphetamines are abused for their euphoric effect and their ability to allow users to remain alert for long periods of time, which explains their popularity among long-distance truck drivers and college students who need to “cram” for exams. One of the most abused of the amphetamines is methamphetamine, also known by the street names meth, crystal, amp, speed, ice, glass, diamond, and crank, among others.
Methamphetamine can be ingested, smoked, snorted, or injected, and it is many times more potent than amphetamine. Oral methamphetamine has a rapid onset of action of 20 to 30 minutes. When methamphetamine is smoked or injected, however, onset is within minutes. The serum half-life of methamphetamine is 12 to 36 hours. The drug’s euphoric and metabolic effects generally last 4 to 6 hours but can last up to 24 to 48 hours, depending on the dose used and the rate of excretion, which is reduced by alkaline urine. Frequent use leads to drug accumulation and prolongation of the clinical effects. At the same time, tachyphylaxis develops, which will require the user to take a higher dose of the drug to achieve the same high. Although there is no physical addiction to methamphetamine, the psychological addiction is particularly strong.
MANIFESTATIONS OF ACUTE TOXICITY
Methamphetamine causes the release of catecholamines and blocks their reuptake. Clinically, this manifests as the sympathomimetic toxidrome, a hypermetabolic state characterized by tachycardia, hypertension, agitation, dilated pupils, and bronchodilatation. The toxicity of methamphetamine is an exaggeration of this sympathomimetic affect. For purposes of identification, acute toxicity can be divided into physiologic, neuropsychological, and musculoskeletal manifestations (see table below).
 |
Manifestations of physiologic toxicity resulting from the exaggerated, hypermetabolic state may include fever, hypertension, and tachycardia. This adrenergic overdrive can have a number of deleterious effects on the cardiovascular system, such as chest pain with cardiac ischemia and myocardial infarction (MI). Arrhythmias are common, especially sinus tachycardia. Ventricular tachycardia, paroxysmal supraventricular tachycardia (PSVT), and torsades de pointes may also occur. Patients may also present with CHF, as was suspected in the patient described; this may be due to acute changes (such as hypertensive crisis or cardiac ischemia) or chronic changes. Long-time users of methamphetamine have an increased risk of coronary artery disease as well as CHF secondary to myocarditis caused by the necrosis of contractile muscle bands in the heart (nonischemic cardiomyopathy).
Methamphetamine use may produce neuropsychological changes such as agitation, aggression, hallucinations, and muscle twitching (called “tweaking”), which may progress to myoclonic jerks, delirium, and seizures. Both ischemic and hemorrhagic strokes have been reported secondary to methamphetamine use; some hemorrhagic strokes have been related to underlying arteriovenous malformations. Spontaneous carotid artery dissection, most likely secondary to hypertension, has been reported. Choreoathetoid movements may also be seen in the methamphetamine user.
Finally, methamphetamine’s effect on skeletal muscle causes bruxism, trismus, and muscle rigidity. Patients may develop rhabdomyolysis with ensuing renal failure from myoglobinuria.
DIFFERENTIAL DIAGNOSIS
The differential diagnosis of methamphetamine toxicity is broad. A patient with an anticholinergic drug overdose may present with similar symptoms, including fever, confusion, mydriasis, and tachycardia. Other stimulants such as methylenedioxymethamphetamine (MDMA, ecstasy), cocaine, and phencyclidine (PCP) may produce similar effects. Among the systemic and neurologic illnesses that may mimic methamphetamine abuse are sepsis (fever, confusion), serotonin (fever, confusion, muscle rigidity), neuroleptic malignant syndrome (fever, confusion, muscle rigidity), thyrotoxicosis/thyroid storm (tachycardia, confusion, fever), and pheochromocytoma (tachycardia, hypertension, agitation).
The diagnosis of methamphetamine abuse is generally made on historical and clinical grounds. However, there are some adjunctive tests that may be helpful in ruling out significant adverse consequences of methamphetamine abuse. An ECG should be done if the patient complains of chest pain or if CHF is suspected. The ECG results and typical cardiac markers, such as creatine phosphokinase (CPK)-MB, troponin, and myoglobin, should be interpreted in the same way as in patients who are not using methamphetamine. Electrolytes, blood urea nitrogen, creatinine, CPK, and urinalysis may reveal evidence of rhabdomyolysis or renal failure.
A positive urine dipstick for hemoglobin in the absence of red blood cells in the urine should suggest myoglobinuria. A glucose level should be obtained in any patient who has mental status changes, and computed tomography should be performed if there is any question of ischemic cerebrovascular accident or central nervous system (CNS) bleeding.
A urine drug screen is of limited usefulness. According to guidelines from the Agency for Healthcare Research and Quality (AHRQ), urine screening for methamphetamine “does not correlate well with clinical effects and suffers from problems with sensitivity and specificity” (see Suggested Reading). Multiple over-the-counter drugs, including herbal products containing ma huang, can cause a false-positive urine test for methamphetamine. So urine tests for methamphetamine use must be interpreted with caution, and the results must always be evaluated in light of the clinical findings. Getting a urine toxicology screen in this situation is a grade B recommendation, according to AHRQ.
CHRONIC SEQUELAE OF METHAMPHETAMINE USE
Perhaps more disturbing than the acute effects of methamphetamine use are its chronic sequelae. One of the most obvious of these is “meth mouth,” which is characterized by extensive caries, mostly on the buccal surface of the teeth and between the anterior teeth (see image). The teeth are often stained black and lose their structural integrity. The cause of meth mouth is multifactorial and likely includes hyposalivation, direct trauma from bruxism, poor attention to dental hygiene, and ingestion of prodigious quantities of acidic, sugary soda to relieve a chronically dry mouth.
|
Meth mouth. One of the more clinically dramatic sequelae of methamphetamine abuse is deterioration of dental health characterized by extensive caries and, often, loss of structural integrity of the teeth.
Photo courtesy Stephen Wagner, DDS
|
Long-term neuropsychological effects also occur. Patients may report sleep disturbance, depression, and suicidal ideation. Amphetamines, including methamphetamine, stimulate dopamine production in the limbic system, inducing a syndrome indistinguishable from schizophrenia that includes paranoia and hallucinations. One particularly disturbing and almost pathognomonic finding is hallucinations of parasitosis, called formication (derived from the Latin word for ant). Patients with formication will complain of a feeling of insects crawling on or under their skin. Often, they will pick at themselves relentlessly in an attempt to remove the parasites. This can lead to open sores and scarring. It is not uncommon for these patients to bring in bits of lint or flakes of skin as “proof” of parasitosis.
Chronic methamphetamine use has been associated with CNS vasculitis, which can manifest as headaches and neurologic deficits. Persistent pulmonary hypertension can result from prolonged exposure to methamphetamine. Long-term use is also associated with cognitive impairment; deficits include psychomotor retardation and short-term memory difficulties. These impairments persist even after drug use is stopped.
METHAMPHETAMINE LABORATORY EXPOSURE
Individuals who produce methamphetamine (“cookers”), as well as first responders such as police and fire fighters, are at risk for exposure to chemical toxins and possible laboratory explosions. Besides anhydrous ammonia, which was mentioned earlier, toxic substances used in the manufacture of methamphetamine include hydrochloric acid, sodium hydroxide, and sulfuric acid. Methamphetamine laboratories are also prone to explosion and fire from the use of ether, acetone, propane, and other solvents. About 20% to 30% of methamphetamine laboratories are found by law enforcement officials as a result of an explosion or fire.
Most of the toxic effects are mild, such as irritation of the mouth, throat, eyes, and lungs. However, significant dyspnea can occur from exposure to pulmonary irritants. Solvents may cause liver and kidney damage and long-term exposure can cause CNS damage. Burn and blast injuries are also common. In one study in Iowa, methamphetamine lab explosions were responsible for 10% of patients admitted to a burn unit with facial burns. Eye injuries are also commonly seen.
The minimum safety equipment for law enforcement include protective eyewear, gloves, and foot covers; a disposable jumpsuit (such as those made of Tyvek) is also recommended. Respirators are required if there is any concern about toxic fumes. A hazardous material team should be contacted when a raid or clean-up of a methamphetamine laboratory is contemplated.
APPROACH TO TREATMENT
Treatment of the patient with a methamphetamine overdose is directed at the physiologic and neuropsychological changes produced by the drug (see table, below). Decontamination is of limited efficacy; there is little that can be done to remove methamphetamine from the body. While it would make sense to acidify the urine to enhance methamphetamine excretion, this is contraindicated. Acidification of the urine can result in precipitation of myoglobin in the renal tubules, which can lead to renal failure. It should also be noted that methamphetamine cannot be removed from the body by hemodialysis.
 |
Hyperthermia should be treated with appropriate fluid management and evaporative cooling. Antipyretics are of no benefit in this situation. Hydration of these patients is crucial; they tend to be hypovolemic from fluid loss, and fluid administration will help prevent myoglobin precipitation in the renal tubules. Hypertension, tachycardia, and vasospasm can be managed with an alpha blocker such as phentolamine or a nitrate such as nitroglycerin or nitroprusside. Nitroprusside may be more effective than nitroglycerin in this setting. Beta blockers should be avoided because they can result in unopposed alpha-receptor stimulation, which would further increase heart rate and exacerbate vasospasm, hypertension, and cardiac ischemia.
Ventricular arrhythmias can be addressed using standard advanced cardiac life support protocols. However, there are no trials assessing the effectiveness of these protocols in this setting. Calcium channel blockers should be used in cases of PSVT, again avoiding beta blockers. Treat MI using standard drugs (aspirin, oxygen, heparin), but avoid beta blockers if possible. Agitation, aggressive behavior, and seizures should be treated with a benzodiazepine such as diazepam or lorazepam. Remember that diazepam is poorly absorbed when given intramuscularly. Avoid haloperidol and droperidol in the methamphetamine user since they can lower the seizure threshold. Muscle rigidity and seizures respond well to benzodiazepines.
PATIENT DISPOSITION
The decision to admit the patient will be dictated by the clinical situation. Patients with chest pain or those with ongoing hypertension or rhabdomyolysis should be admitted using the same criteria that are used in making admission decisions for other patients, with the caveat that active drug may be present for up to 24 hours or more. Thus, patients requiring nitroglycerin and nitroprusside or phentolamine to control their blood pressure should be admitted. Likewise, those with chest pain that is suspected to be of a cardiac nature should be admitted. If possible, psychiatric and substance abuse referrals should be made.
back to top
Suggested Reading
Agency for Healthcare Research and Quality (Web site): Screening and ongoing assessment of substance abuse. Available at http://www.guideline.gov/summary/
summary. aspx?doc_id=6848&nbr=004202&string=methamphetamine. Accessed March 7, 2007.
Charukamnoetkanok P and Wagoner MD: Facial and ocular injuries associated with methamphetamine production accidents. Am J Ophthalmol 138(5):875, 2004.
Derlet RW and Heischober B: Methamphetamine: stimulant of the 1990s? West J Med 153(6):625, 1990.
Drug Abuse Warning Network. Available at http://dawninfo.samhsa.gov (Web site). Accessed March 7, 2007.
Grant P: Evaluation of children removed from a methamphetamine laboratory. Clin Ped Emerg Med 1:170, 2006.
Rusyniak DE and Sprague JE: Toxin-induced hyperthermic syndromes. Med Clin North Am 89(6):1277, 2005.
Shaner JW, et al.: “Meth mouth”: rampant caries in methamphetamine abusers. AIDS Patients Care STDS 20(3):146, 2006. |
|
